Synergistic inhibition of platelet aggregation by endothelium derived relaxing factor and prostacyclin
- 1 March 1988
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 49 (5) , 437-449
- https://doi.org/10.1016/s0049-3848(98)90001-9
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factorNature, 1987
- Endothelium‐derived relaxing factor inhibits in vitro platelet aggregationBritish Journal of Pharmacology, 1987
- Stabilization and partial characterization of endothelium-derived relaxing factor from cultured bovine aortic endothelial cellsBiochemical and Biophysical Research Communications, 1986
- Endothelium‐dependent inhibition of platelet aggregationBritish Journal of Pharmacology, 1986
- Bioassay of prostacyclin and endothelium‐derived relaxing factor (EDRF) from porcine aortic endothelial cellsBritish Journal of Pharmacology, 1986
- Release and properties of endothelium‐derived relaxing factor (EDRF) from endothelial cells in cultureJournal of Cellular Physiology, 1985
- The Pharmacological and Physiological Role of Cyclic GMP in Vascular Smooth Muscle RelaxationAnnual Review of Pharmacology and Toxicology, 1985
- The use of prostacyclin in the separation from plasma and washing of human plateletsProstaglandins, 1982
- Evidence for the inhibitory role of guanosine 3', 5'-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilatorsBlood, 1981
- Arachidonic Acid Metabolites and the Interactions between Platelets and Blood-Vessel WallsNew England Journal of Medicine, 1979